Meiri Kawazoe-Shida

Chugai Life Science Park Yokohama, 216 Totsuka Cho, Totsuka Ku
Yokohama, 2448602, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling.

Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling.

Journal: The AAPS journal

Published: December 03, 2025

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.

Journal: Communications medicine

Published: December 02, 2024

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Journal: International journal of molecular sciences

Published: October 02, 2024

Novel myostatin-specific antibody enhances muscle strength in muscle disease models.

Novel myostatin-specific antibody enhances muscle strength in muscle disease models.

Journal: Scientific reports

Published: November 26, 2020

Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.

Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.

Journal: Cancer discovery

Published: March 17, 2020

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Journal: PloS one

Published: September 10, 2018

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Journal: Scientific reports

Published: December 21, 2016

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Journal: mAbs

Published: February 15, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026